IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
type: Dataset
description: International audience
issued: 2026-05-08T04:18:51.371748
language: en
modified: 2026-05-08T04:18:51.371752
contact point: Organization
  fn: CCSD
keyword: infoeu-reposemanticsarticle
keyword: jak3
keyword: journal-articles
keyword: kidney-transplantation
keyword: mesh-antineoplastic-agents
keyword: mesh-apoptosis
keyword: mesh-apoptosis-regulatory-proteins
keyword: mesh-bcl-2-associated-x-protein
keyword: mesh-cd8-positive-t-lymphocytes
keyword: mesh-cell-line-tumor
keyword: mesh-cytokines
keyword: mesh-dose-response-relationship-drug
keyword: mesh-humans
keyword: mesh-janus-kinase-3
keyword: mesh-jurkat-cells
keyword: mesh-membrane-proteins
keyword: mesh-phosphatidylinositol-3-kinases
keyword: mesh-proto-oncogene-proteins
keyword: mesh-proto-oncogene-proteins-c-akt
keyword: mesh-stat5-transcription-factor
keyword: mesh-t-lymphocytes
keyword: mesh-time-factors
keyword: sdvbclife-sciences-q-biocellular-biology
keyword: tofacitinib
landing page: 1350-9047

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
type: Distribution
format: HTML
issued: 2026-05-08T04:18:51.398908
modified: 2026-05-08T04:18:51.348132
access URL: https://inserm.hal.science/inserm-00906808

test_moissonnage_selune
type: Agent